Dr. Nizar Bahlis on Elranatamab

What is the background of this study? 

Elranatamab (PF-06863135) is a humanized bispecific monoclonal antibody (IgG2a) that targets BCMA, a member of the tumor necrosis factor receptor superfamily expressed in MM, and CD3 on T cells. We reported results for intravenous (IV) dosing (Raje et al. Blood. 2019;134(S1):1869) and now update for subcutaneous (SC) dosing from the ongoing Phase 1 study (MagnetisMM-1).

In this video:

Dr. Nizar Bahlis (University of Calgary, Calgary, AB, Canada_ discusses the efficacy and safety of elranatamab in relapsed refractory  multiple myeloma.

Conclusions:

Elranatamab demonstrated a manageable safety profile, and subcutaneous (SC) doses ≥215μg/kg achieved overall response rate of 75% with complete response/stringent complete response rate of 30%. These results demonstrate the safety and efficacy of SC elranatamab in this relapsed/refractory population and support ongoing development of elranatamab for patients with multiple myeloma, both as monotherapy and in combination with standard or novel therapies. 

Clinical trial information: NCT03269136 (http://clinicaltrials.gov/show/NCT03269136)